SEC Comment Letter for Acurx Pharmaceuticals, Inc. (ACXP) (CIK 0001736243) (ACXP) — May 7, 2026
Acurx Pharmaceuticals, Inc. (ACXP) (CIK 0001736243)
Date: May 7, 2026 · CIK: 0001736243 · Accession: 0000000000-26-004693
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295528
Letter
May 7, 2026 David P. Luci President and Chief Executive Officer Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, New York 10305 Re: Acurx Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed No. 333-295528 Filed May 4, 2026 Dear David P. Luci: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ivan K. Blumenthal, Esq.
Show Raw Text
May 7, 2026 David P. Luci President and Chief Executive Officer Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, New York 10305 Re: Acurx Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed No. 333-295528 Filed May 4, 2026 Dear David P. Luci: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ivan K. Blumenthal, Esq.